Matsakaicin Magani na CBL‑514 – Menene Kimiyyar Sa?
Karanta wannan da farko: CBL‑514 wani ƙwayar magani ne da ake bincike ta hanyar allura a cikin gwaje‑gwajen likita. Ba allura ce da za a sha ba, ba ƙari ba, ba samfur da aka amince da shi ba, kuma ba shawarar likita ba ce. Adadin “600 mg” da ake gani a yanar gizo shi ne iyakar adadin da ake amfani da shi a kowanne magani a cikin tsarin gwaji – ba adadin da za a iya ci ko shan ba. (Lura: CBL‑514, ba “CL‑514”).
CBL‑514 kamfani ne daga Caliway Biopharmaceuticals kuma ana kiransa a matsayin ƙananan ƙwayar maganin allura da ke rage kitse. A takardun, ana bai wa majinyata allurar sub‑cutaneous a cikin ƙirjin ƙirji. Manufar da kamfanin ke bayyana (cikin rahotannin da ba a wallafa ba) ita ce kashe ƙwayoyin kitse (adipocytes) ta hanyar apoptosis. Ba zai ƙara saurin metabolism ba, ba “ƙone kitse” ba, kuma ba ragin nauyin jiki gaba ɗaya ba. Takardun ba su bayyana tsarin sinadarin ba.
Mataki na ɗaya: Binciken Phase 2a na ƙayyade ƙima
Binciken da aka yi shi ne Goodman et al., Aesthetic Surgery Journal 2022 (PMC9384315). An gudanar da shi buɗe‑label ba tare da placebo ba, kuma ƙaramar ƙungiya ne: n=43, an raba su 7 / 18 / 18 a tsakanin matakan ƙima uku.
An ayyana ƙimar a kan kowanne centimita murabba'i (cm²) na fata da aka magance, a kan yanki na 150 cm²:
| Matsakaicin ƙima (mg/cm²) | Jimillar adadin da aka yi amfani da shi (150 cm²) |
|---|---|
| 1.2 | 180 mg |
| 1.6 | 240 mg |
| 2.0 | 300 mg |
An yi allura 60 a cikin makonni 2. Adadin mg kawai shi ne ƙimar ƙarfi a kan yanki da aka ninka. Misali, 2.0 mg/cm² × 150 cm² = 300 mg.
Takardar ta ba da rahoton ragin kashi‑kashi (ITT) ga kowanne rukunin, kuma masu karatu su duba takardar don ganin cikakken ƙididdiga. Lambar da aka fi ambata ita ce 24.96 %. Wannan sakamakon na Per‑Protocol (PP) ne, ga rukunin 2.0 mg/cm², a biyo‑bayan farko, inda aka samu −119.82 mL na ragin kitse. Sakamakon PP yana ƙididdige ne kawai mahalarta da suka bi tsarin da aka tsara, ba ya wakiltar sakamako ga dukkan mahalarta ba.
Mataki na biyu: Phase 2 da aka gwada da placebo
Babban takarda itace Gold et al., Aesthetic Surgery Journal 2025;45(6):611‑620 (PMC12080885; PubMed; DOI). An gudanar da shi a matsayin randomized, single‑blind (mahalarta kawai) kuma placebo‑controlled, a cibiyoyi biyar a Amurka da Australia.
Matsakaicin ƙima an tsaya a 2.0 mg/cm². Duk abin da ya canza shine:
- Yankin magani: 300 cm² (ninka yanki na Phase 2a).
- Yawan allura: 25‑50 a kowanne magani, bisa shawarar mai bincike dangane da adadin kitse a ƙirjin.
- Kowane allura: 2.4 mL, an rarraba su da tazara na 2.45 cm.
- Iyaka: har 600 mg a kowanne magani (2.0 mg/cm² × 300 cm²).
- Tsarin lokaci: har zuwa magani 4 a makonni 4, tare da biyo‑bayan a makonni 4 da 8 bayan magani na ƙarshe.
- Kamar yadda aka kwatanta: saline na yau da kullum da aka ba da a girman daidai.
An raba placebo (saline) da ƙididdiga 2:1.
Dalilin da yasa jimillar mg ba za a iya musanya su ba
Canjin daga 300 mg zuwa 600 mg ba yana nufin an ninka ƙimar magani a wani yanayi na halitta ba. ƙimar a kan yanki ta kasance guda: 2.0 mg/cm². Abin da ya canza shine yanki da aka yi magani, adadin allura, tazara tsakanin lokuta, da tsarin lokaci. Jimillar mg kawai tana da ma’ana idan an haɗa da waɗannan bayanai.
Saboda haka fassarar “600 mg” a matsayin ƙimar ƙari ba daidai ba ce. Lambar nan tana nuni ne ga iyaka ga jerin allura da aka tsara bisa yanki, ba ga abin da mutum zai sha ba a waje da wannan tsari.
Babu gwajin kai tsaye tsakanin ƙimar ƙima a Phase 2
Phase 2 ba ta raba mahalarta zuwa ƙimar ƙima daban‑daban ba tare da placebo ba. 2.0 mg/cm² an kulle shi bisa ga aikin farko. Don haka hujjar da aka samu daga gwajin placebo tana tallafawa wannan ƙimar guda, ba ƙirƙira sabon tsari ba. Kawai gwajin buɗe‑label na Phase 2a ne ke da matsakaicin ƙima uku, kuma ba shi da armar placebo.
Abin da Phase 2 ta gano a wannan tsari
Masu bincike sun ba da rahoton cikar manufofin farko da na biyu. A cikin nazarin ITT, 63.9 % (23/36) na mahalarta da suka samu CBL‑514 sun rasa aƙalla 150 mL na ragin kitse a ɓangaren ƙirji a biyo‑bayan mako 4, idan aka kwatanta da 17.4 % (4/23) a placebo. A mako 8, adadin ya kai 69.6 % (16/23) vs 0 % (0/16). Adadin mahalarta ya ragu saboda rashin cikakken bayanan biyo‑bayan.
Matsakaicin bambanci tsakanin ƙungiyoyi ya kasance −206.62 mL a mako 4 da −216.28 mL a mako 8. An ƙididdige girman kitse daga ultrasound a maki huɗu da yanki na 300 cm², ba a auna kai tsaye ba.
Mahimman gargadi:
- Daga mahalarta 75 da aka yi magani, 37 (49.3 %) ba su kammala ba.
- Ƙungiyar PP ita ce 30 kawai.
- Mai tallafa ya taka rawa a ƙirƙira, nazari da rubutu.
- Masu bincike ba su rufe ido ba.
- Girman samfurin ƙanana ne, na bincike ne kawai.
- Nauyin jiki bai canza sosai ba, don haka wannan rage girman kitse na wuri‑wuri ne, ba ragin nauyi ba.
Tsaro a matakan gwaji
An bi sahihan al'amuran tsaro ta hanyar rikodin abubuwan da suka faru bayan magani, gwajin jini, sigogi, ECG, duban jiki, da kuma amsoshin wurin allura da aka rubuta a matsayin al'amuran daban‑daban a kowane magani. Ayyukan wurin allura sune manyan abubuwan da za a iya tsammani daga tsari da ke da manyan injekshani a kowane zaman. Masu karatu su duba takardun don ganin adadin ainihi, ciki har da yawan zafi mai tsanani, maimakon dogaro da takaitattun bayanai. Daga mahalarta 37 da ba su kammala ba a Phase 2, huɗu sun bar saboda abubuwan da suka faru.
A Phase 2a, ƙungiyar bincike ta yi amfani da matakan kamar anesthetic, kankara, da antihistamine. Wannan ba shawarar likita ba ne, yana nuna yadda masu bincike suka sarrafa aikin gwaji, ba abin da kowa zai yi da kansa ba.
Takardun sun kuma lura da alamun lipids a wasu mahalarta da ke da manyan lipids tun farko. Wannan ƙaramar abu ne a cikin mutane kaɗan, ba a tabbatar da tasirin metabolic ba. Babu wani abu a cikin waɗannan gwaje‑gwajen da ya tabbatar da tasirin tsarin jiki na CBL‑514.
Abin da masu sha’awar “bio‑hacking” ya kamata su fahimta
Kimiyyar CBL‑514 ta ƙunshi gwaji ƙanana buɗe‑label da ya kwatanta ƙima uku a kan yanki, sannan babban gwaji single‑blind da ya yi amfani da ɗaya daga cikinsu (2.0 mg/cm²) a kan yanki mai faɗi tare da iyaka mafi girma a kowanne zaman. Karanta “600 mg” a matsayin ƙimar alama yana rasa duk wannan.
CBL‑514 ba a amince da shi ba, ba samfurin masu amfani ba, kuma wannan makala ba shawarwarin likita ba ne.